These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19016571)
1. Mild to moderate Crohn's disease: an evidence-based treatment algorithm. Wong K; Bressler B Drugs; 2008; 68(17):2419-25. PubMed ID: 19016571 [TBL] [Abstract][Full Text] [Related]
2. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Sandborn WJ; Feagan BG Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211 [TBL] [Abstract][Full Text] [Related]
3. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Brookes MJ; Green JR Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787 [TBL] [Abstract][Full Text] [Related]
4. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Sandborn WJ; Feagan BG; Lichtenstein GR Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506 [TBL] [Abstract][Full Text] [Related]
5. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Panaccione R; Steinhart AH; Bressler B; Khanna R; Marshall JK; Targownik L; Afif W; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C; Bernstein CN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1680-1713. PubMed ID: 30853616 [TBL] [Abstract][Full Text] [Related]
6. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Lichtenstein GR; Hanauer SB; Kane SV; Present DH Inflamm Bowel Dis; 2004 Jul; 10 Suppl 2():S2-10. PubMed ID: 15475770 [TBL] [Abstract][Full Text] [Related]
7. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Feagan BG; Sandborn WJ Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239 [TBL] [Abstract][Full Text] [Related]
9. Review article: medical treatment of mild to moderately active Crohn's disease. Löfberg R Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():18-22. PubMed ID: 12786608 [TBL] [Abstract][Full Text] [Related]
10. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E; Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560 [TBL] [Abstract][Full Text] [Related]
18. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going? Naseer M; Poola S; Ali S; Samiullah S; Tahan V Curr Clin Pharmacol; 2020; 15(3):216-233. PubMed ID: 32164516 [TBL] [Abstract][Full Text] [Related]
19. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Clemett D; Markham A Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042 [TBL] [Abstract][Full Text] [Related]
20. Review article: the limitations of corticosteroid therapy in Crohn's disease. Rutgeerts PJ Aliment Pharmacol Ther; 2001 Oct; 15(10):1515-25. PubMed ID: 11563990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]